TNGX
Income statement / Annual
Last year (2024), Tango Therapeutics, Inc.'s total revenue was $42.07 M,
an increase of 15.17% from the previous year.
In 2024, Tango Therapeutics, Inc.'s net income was -$130.30 M.
See Tango Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$42.07 M |
$36.53 M |
$24.86 M |
$37.04 M |
$7.66 M |
$24.65 M |
| Cost of Revenue |
$0.00
|
$115.20 M
|
$4.03 M
|
$1.97 M
|
$1.63 M
|
$32.27 M
|
| Gross Profit |
$42.07 M
|
-$78.67 M
|
$20.83 M
|
$35.08 M
|
$6.03 M
|
-$7.63 M
|
| Gross Profit Ratio |
1
|
-2.15
|
0.84
|
0.95
|
0.79
|
-0.31
|
| Research and Development Expenses |
$143.92 M
|
$115.20 M
|
$105.91 M
|
$77.64 M
|
$49.99 M
|
$32.27 M
|
| General & Administrative Expenses |
$43.75 M
|
$35.50 M
|
$30.03 M
|
$17.60 M
|
$9.87 M
|
$7.54 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$43.75 M
|
$35.50 M
|
$30.03 M
|
$17.60 M
|
$9.87 M
|
$7.54 M
|
| Other Expenses |
$0.00
|
$0.00
|
$2.95 M
|
$247,000.00
|
$120,000.00
|
$0.00
|
| Operating Expenses |
$187.66 M
|
$150.70 M
|
$135.93 M
|
$95.23 M
|
$59.86 M
|
$7.15 M
|
| Cost And Expenses |
$187.66 M
|
$150.70 M
|
$135.93 M
|
$95.23 M
|
$59.86 M
|
$39.43 M
|
| Interest Income |
$7.89 M
|
$6.62 M
|
$1.46 M
|
$495,000.00
|
$108,000.00
|
$684,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$2.42 M
|
$4.03 M
|
$1.97 M
|
$1.63 M
|
$643,000.00
|
| EBITDA |
-$145.60 M |
-$111.76 M |
-$109.46 M |
-$57.29 M |
-$51.48 M |
-$14.52 M |
| EBITDA Ratio |
-3.46
|
-3.06
|
-4.47
|
-1.57
|
-6.72
|
-0.59
|
| Operating Income Ratio |
-3.46
|
-3.13
|
-4.47
|
-1.57
|
-6.82
|
-0.62
|
| Total Other Income/Expenses Net |
$15.50 M
|
$12.56 M
|
$2.95 M
|
$247,000.00
|
$228,000.00
|
$1.07 M
|
| Income Before Tax |
-$130.09 M
|
-$101.61 M
|
-$108.12 M
|
-$57.94 M
|
-$51.97 M
|
-$14.10 M
|
| Income Before Tax Ratio |
-3.09
|
-2.78
|
-4.35
|
-1.56
|
-6.79
|
-0.57
|
| Income Tax Expense |
$208,000.00
|
$134,000.00
|
$54,000.00
|
$292,000.00
|
-$108,000.00
|
$0.00
|
| Net Income |
-$130.30 M
|
-$101.74 M
|
-$108.18 M
|
-$58.24 M
|
-$51.86 M
|
-$14.10 M
|
| Net Income Ratio |
-3.1
|
-2.79
|
-4.35
|
-1.57
|
-6.77
|
-0.57
|
| EPS |
-1.19 |
-1.08 |
-1.23 |
-0.94 |
-1.62 |
-1.57 |
| EPS Diluted |
-1.19 |
-1.08 |
-1.23 |
-0.94 |
-1.62 |
-1.57 |
| Weighted Average Shares Out |
$109.23 M
|
$94.57 M
|
$87.82 M
|
$62.11 M
|
$31.93 M
|
$8.99 M
|
| Weighted Average Shares Out Diluted |
$109.23 M
|
$94.57 M
|
$87.82 M
|
$62.11 M
|
$31.93 M
|
$8.99 M
|
| Link |
|
|
|
|
|
|
